01—Abstract
Summary
Summary of the 8-K filed August 7, 2024. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. (NYSE: CRL) reported second-quarter 2024 results on August 7, 2024 (quarter ended June 29, 2024).
Revenue was $1.03 billiona, down 3.2% from $1.06 billion a year earlier, with organic revenue also declining 3.2%. GAAP diluted EPS was $1.74, down 7.9% from $1.89, while non-GAAP diluted EPS rose 4.1% to $2.80 from $2.69, driven mainly by lower performance-based compensation accruals and higher Manufacturing Solutions revenue and operating income. The Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments both declined on an organic basis, at 5.0% and 3.9% respectively, while Manufacturing Solutions grew 3.7% organically.
The company materially cut its 2024 outlook. Reported revenue growth guidance is now (4.5)% to (2.5)%, down from 1.0% to 4.0%, and organic growth is now (5.0)% to (3.0)%, versus 0.0% to 3.0% previously. GAAP EPS guidance fell to $5.65b–$5.95 from $7.60–$8.10, and non-GAAP EPS guidance fell to $9.90–$10.20 from $10.90–$11.40.
Management attributed the revision to a lack of demand recovery from small and mid-sized biotech clients and softer trends from global biopharmaceutical clients, and said it no longer expects demand to improve in the second half of 2024. To address this, the Board approved a new $1.0 billionc stock repurchase authorization, replacing a prior $1.3 billion program that had $129.1 million remaining when terminated. Restructuring initiatives are expected to yield annualized cost savings of over $150 million (including actions taken since last year through Q3 2024), with approximately $100 million realized in 2024.
02—Key points
Key Highlights
- Q2 2024 revenue of $1.03 billion decreased 3.2% year over year; organic revenue also declined 3.2%.
- GAAP diluted EPS of $1.74 fell 7.9% from $1.89; non-GAAP diluted EPS rose 4.1% to $2.80 from $2.69.
- DSA segment revenue fell 5.4% to $627.4 million (organic decline of 5.0%); RMS revenue fell 1.7% to $206.4 million, with NHP revenue in China a primary driver.
- Manufacturing Solutions revenue rose 3.1% to $192.3 million, with organic growth of 3.7% and GAAP operating margin up to 19.4% from 13.1%.
- 2024 reported revenue growth guidance cut to (4.5)%–(2.5)% from 1.0%–4.0%; non-GAAP EPS guidance cut to $9.90–$10.20 from $10.90–$11.40.
- Board approved a new $1.0 billion stock repurchase authorization, replacing a prior $1.3 billion program with $129.1 million remaining.
- Restructuring initiatives expected to deliver annualized cost savings of over $150 million, with about $100 million realized in 2024.
03—Questions
Frequently Asked Questions
Why did Charles River lower its 2024 guidance?
The company cited no recovery in demand from small and mid-sized biotechnology clients in the second half of 2024 and softer demand from global biopharmaceutical clients, which it said had become increasingly evident over the prior couple of months. It no longer expects overall demand trends to improve in the second half, with a meaningful impact on the DSA segment.
How did earnings perform on a GAAP versus non-GAAP basis?
GAAP diluted EPS was $1.74, down 7.9% from $1.89, driven by lower revenue and operating income and higher restructuring costs. Non-GAAP diluted EPS was $2.80, up 4.1% from $2.69, mainly due to lower performance-based compensation accruals and higher Manufacturing segment revenue and operating income.
What is the new stock repurchase program?
The Board approved a new $1.0 billion stock repurchase authorization. It replaces a prior $1.3 billion authorization that had $129.1 million remaining when it was terminated.
What restructuring actions is the company taking?
The company is implementing restructuring initiatives expected to produce annualized cost savings of over $150 million, inclusive of actions implemented from last year through Q3 2024, of which approximately $100 million will be realized in 2024. The filing also notes site consolidation costs related to CRADL operations in California within RMS.
Which segments drove the revenue decline?
On an organic basis, DSA revenue fell 5.0% on lower Discovery Services and Safety Assessment revenue, and RMS fell 3.9%, due mainly to lower non-human primate revenue in China. Manufacturing Solutions grew 3.7% organically, partially offsetting the declines.
04—Continue